215 related articles for article (PubMed ID: 23247325)
1. Anti-tumor necrosis factor agents and placental transfer: relevant clinical data for rational decision-making.
Kane S
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):293-4. PubMed ID: 23247325
[No Abstract] [Full Text] [Related]
2. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
Mahadevan U; Wolf DC; Dubinsky M; Cortot A; Lee SD; Siegel CA; Ullman T; Glover S; Valentine JF; Rubin DT; Miller J; Abreu MT
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):286-92; quiz e24. PubMed ID: 23200982
[TBL] [Abstract][Full Text] [Related]
3. IBD: Can TNF inhibitors be administered during the third trimester?
Nielsen OH; Jess T
Nat Rev Gastroenterol Hepatol; 2013 Mar; 10(3):130-1. PubMed ID: 23247511
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics of biologics and the role of therapeutic monitoring.
Lin K; Mahadevan U
Gastroenterol Clin North Am; 2014 Sep; 43(3):565-79. PubMed ID: 25110259
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
6. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
7. The use of biologic agents in pregnancy and breastfeeding.
Horst S; Kane S
Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
[TBL] [Abstract][Full Text] [Related]
8. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
9. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
10. The classics in perspective.
Panés J; Ghosh S
Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
[No Abstract] [Full Text] [Related]
11. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
Chang JT; Lichtenstein GR
Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
[TBL] [Abstract][Full Text] [Related]
12. [Main therapeutic advances in IBD in 2007].
Felley C; Mottet C; Maillard MH; Hess J; Delarive J; Michetti P
Rev Med Suisse; 2008 Jan; 4(141):200, 202-4, 206-8 passim. PubMed ID: 18335885
[TBL] [Abstract][Full Text] [Related]
13. [Anti-tumor necrosis factor-α medications and pregnancy].
Simon PC; Vallano A
Med Clin (Barc); 2013 Sep; 141(6):257-9. PubMed ID: 23702347
[No Abstract] [Full Text] [Related]
14. [Current status of new drug development for inflammatory bowel diseases].
Kohgo Y; Tanabe H; Fujiya M
Nihon Rinsho; 2012 Feb; 70 Suppl 1():378-82. PubMed ID: 23126121
[No Abstract] [Full Text] [Related]
15. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.
Palframan R; Airey M; Moore A; Vugler A; Nesbitt A
J Immunol Methods; 2009 Aug; 348(1-2):36-41. PubMed ID: 19567252
[TBL] [Abstract][Full Text] [Related]
16. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
17. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
Molnár T
Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
[TBL] [Abstract][Full Text] [Related]
18. Biologic therapies in inflammatory bowel disease.
Cohen LB; Nanau RM; Delzor F; Neuman MG
Transl Res; 2014 Jun; 163(6):533-56. PubMed ID: 24467968
[TBL] [Abstract][Full Text] [Related]
19. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
Roseira J; Ramos J
Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
[TBL] [Abstract][Full Text] [Related]
20. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
